Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.23 Average PT from Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has earned an average rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $3.2250.

A number of brokerages recently commented on LXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th.

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock opened at $1.50 on Monday. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The firm has a market cap of $545.10 million, a P/E ratio of -7.89 and a beta of 0.71. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $1.83. The firm has a 50-day moving average of $1.31 and a 200-day moving average of $1.28.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 52.90% and a negative net margin of 96.77%.The company had revenue of $14.18 million for the quarter, compared to the consensus estimate of $5.81 million. Sell-side analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. raised its position in shares of Lexicon Pharmaceuticals by 15.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 901,222 shares of the biopharmaceutical company’s stock worth $1,036,000 after acquiring an additional 122,010 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its stake in Lexicon Pharmaceuticals by 400.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 26,000 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Lexicon Pharmaceuticals in the third quarter worth $3,240,000. Jacobs Levy Equity Management Inc. bought a new position in Lexicon Pharmaceuticals in the third quarter worth $935,000. Finally, Millennium Management LLC lifted its position in Lexicon Pharmaceuticals by 133.1% during the third quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock valued at $5,171,000 after buying an additional 2,187,396 shares during the period. 74.70% of the stock is owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.